BioPlus: 2026 Q1 Revenue Growth Continues, Dividend Approved

Consolidated Q1 2026 revenue: 26.5 billion KRW, up 15.4% YoY (vs 23.0 billion in Q1 2025)
Separate operating profit: 3.1 billion KRW; consolidated operating profit: 5.7 billion KRW
Consolidated net income attributable to controlling interests: 6.7 billion KRW, down 13% YoY (vs 7.7 billion)
Cash dividend for FY2025 approved: total 4.3 billion KRW (accrued as unpaid dividends), estimated ~70 KRW per share
Allowance for doubtful accounts ratio at 33.6%, indicating high trade receivables risk
Large-scale investment continues: construction in progress for Eumseong plant at 134.5 billion KRW
Convertible bonds of 47.1 billion KRW, borrowings of 16.3 billion KRW; total liabilities 98.5 billion KRW; debt-to-equity ratio 37.9%
Price Return Swap (PRS) contract outstanding on 2.63 million shares, recorded as derivative liability